JP2020531593A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531593A5 JP2020531593A5 JP2020533357A JP2020533357A JP2020531593A5 JP 2020531593 A5 JP2020531593 A5 JP 2020531593A5 JP 2020533357 A JP2020533357 A JP 2020533357A JP 2020533357 A JP2020533357 A JP 2020533357A JP 2020531593 A5 JP2020531593 A5 JP 2020531593A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- phenyl
- substituted
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1713962.7A GB201713962D0 (en) | 2017-08-31 | 2017-08-31 | Compounds |
| GB1713962.7 | 2017-08-31 | ||
| PCT/EP2018/073431 WO2019043139A1 (en) | 2017-08-31 | 2018-08-31 | FUSED [1,2,4] THIADIAZINE DERIVATIVES AS KAT INHIBITORS OF THE MYST FAMILY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531593A JP2020531593A (ja) | 2020-11-05 |
| JP2020531593A5 true JP2020531593A5 (https=) | 2021-10-14 |
| JP6975860B2 JP6975860B2 (ja) | 2021-12-01 |
Family
ID=60050736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020533357A Expired - Fee Related JP6975860B2 (ja) | 2017-08-31 | 2018-08-31 | Ｍｙｓｔファミリーのｋａｔ阻害剤として作用する縮合［１，２，４］チアジアジン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210380548A1 (https=) |
| EP (1) | EP3676266A1 (https=) |
| JP (1) | JP6975860B2 (https=) |
| CA (1) | CA3073794A1 (https=) |
| GB (1) | GB201713962D0 (https=) |
| WO (1) | WO2019043139A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112028850B (zh) * | 2019-06-03 | 2023-05-02 | 鲁南制药集团股份有限公司 | 一种帕瑞昔布钠的中间体化合物 |
| CN112028851B (zh) * | 2019-06-03 | 2023-05-02 | 鲁南制药集团股份有限公司 | 一种帕瑞昔布钠中间体化合物 |
| WO2021030278A1 (en) * | 2019-08-12 | 2021-02-18 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| TW202216131A (zh) | 2020-07-15 | 2022-05-01 | 美商輝瑞大藥廠 | 用於癌症治療之ｋａｔ６抑制劑方法及組合 |
| US20250145637A1 (en) | 2021-08-10 | 2025-05-08 | Jiangsu Hengrui Pharmaceuticals Co. Ltd. | Sulfonamide derivative, preparation method therefor and medical use thereof |
| WO2024023703A1 (en) | 2022-07-29 | 2024-02-01 | Pfizer Inc. | Dosing regimens comprising a kat6 inhibitor for the treatment of cancer |
| AU2024217108A1 (en) | 2023-02-10 | 2025-09-18 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Crystalline form of sulfonamide derivative and preparation method therefor |
| EP4689660A1 (en) | 2023-03-30 | 2026-02-11 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0938477A4 (en) * | 1996-11-13 | 1999-12-29 | Cephalon Inc | BENZOTHIAZOLO AND RELATED HETEROCYCLIC GROUPS CONTAINING CYSTEIN AND SERINE PROTEASE INHIBITORS |
| DE102005055355A1 (de) * | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate |
| GB201510019D0 (en) * | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
-
2017
- 2017-08-31 GB GBGB1713962.7A patent/GB201713962D0/en not_active Ceased
-
2018
- 2018-08-31 JP JP2020533357A patent/JP6975860B2/ja not_active Expired - Fee Related
- 2018-08-31 EP EP18762297.2A patent/EP3676266A1/en not_active Withdrawn
- 2018-08-31 CA CA3073794A patent/CA3073794A1/en not_active Abandoned
- 2018-08-31 US US16/642,290 patent/US20210380548A1/en not_active Abandoned
- 2018-08-31 WO PCT/EP2018/073431 patent/WO2019043139A1/en not_active Ceased